Catalog Number:82030

IntelliPlex™ Lung Cancer Panel - cfDNA

The IntelliPlex™ Lung Cancer Panel comprises NSCLC driver genes' DNA mutations and RNA fusion variants detection for use with samples extracted from NSCLC formalin-fixed paraffin-embedded tissues (FFPET) or liquid biopsies such as plasma. The cfDNA panel is a qualitative molecular assay for the detection of 74 DNA mutation hotspots in the KRAS, NRAS, PIK3CA, BRAF, EGFR, HER2, MEK1 and AKT1 genes from plasma samples in a single well by using PlexBio's core πCode technology.

FEATURES
  • Detect 8 driver genes, 74 mutation hotspots in one well test
  • Highly sensitive (0.1~2.32%) to detect low levels of mutant DNA
  • Only ≥10ng DNA sample required
  • Time to results in <6 hours for 96 samples per run (sample preparation included)
broad coverage

Broad Target Coverage

Detectable 8 driver genes,
74 DNA mutations in one well
sample

Low Sample Input

Only 10ng DNA sample extracted from FFPE tissues required
high sensitivity

High Sensitivity

Detects low levels of mutant DNA with a high sensitivity
quick turnaround time

Quick Turnaround Time

Sample to results in <6 hours with automated reporting 
Overview
Most cases of lung cancer are sporadic, rather than hereditary, but several genes and even types of specific mutations are commonly seen in these sporadic cases. Due to the genetic diversity in lung cancers, a comprehensive and rapid test that access multiple genes' mutation profile simultaneously with a high level of accuracy, rather than individual gene testing is crucial and unmet need. Moreover, results are intended to assist clinicians in identifying patients who may benefit from available targeted treatments to achieve the personalized cancer management.

The IntelliPlexTM Lung Cancer Panel- cfDNA is an in-vitro molecular test based on πCodeTM technology and PlexBio's instrument platform to identify 74 DNA mutations in KRAS, NRAS, PIK3CA, BRAF, EGFR, HER2, MEK1 and AKT1 genes in NSCLC. πCode technology enables the multi-mutations detection in single-well with DNA samples derived from plasma. The kit provides all necessary optimized reagents for the sensitive detection of low levels of mutant DNA in a background of wild-type genomic DNA by simultaneous PCR amplification of target mutations. The genetic status evaluation from these NSCLC driver genes can impact the selection of and the response to targeted therapies.


Principle of πCode Multiplexing
OUR RESOURCES
IFU
Type
IFU
Publish Date
2022.05.06

您目前為透過後台登入模式

Please Enable cookies to improve your user experience

Continue